BEF, Author at The Boomer Esiason Foundation

March 19, 2019

PTC Therapeutics, Inc. announced today that it has completed enrollment of a Phase 3 clinical trial of ataluren, an investigational new drug, in patients with nonsense mutation cystic fibrosis (nmCF). The 48-week study is designed to determine whether ataluren can improve lung function in patients with...

Denufosol Phase 3 Trial Published in Leading Medical Journal

by BEF

CF Community, CF News, Therapies

March 19, 2019

Inspire Pharmaceuticals, Inc. announced today that the results from its first Phase 3 clinical trial with denufosol tetrasodium for cystic fibrosis (CF), TIGER-1, have been published in the peer-reviewed publication, American Journal of Respiratory and Critical Care Medicine (AJRCCM). Denufosol is an investigational, inhaled, novel...

New England Journal of Medicine Publishes Phase 2 Study of VX-770 for Treating Cause of CF

by BEF

CF News, Therapies

March 19, 2019

In a study published in this week’s New England Journal of Medicine, treatment with a new drug candidate known as VX-770 resulted in improvements in lung function and markers of disease in a Phase 2 clinical trial of 39 people with cystic fibrosis. There were...

Phase 2 Results Show Ataluren Restores Production of Functional CFTR Protein

by BEF

CF News, Therapies

March 19, 2019

PTC Therapeutics, Inc. today announced the publication of data from a Phase 2a clinical trial of ataluren in children with nonsense mutation cystic fibrosis (nmCF) in the American Journal of Respiratory and Critical Care Medicine. The published data show that treatment with ataluren, an investigational...

Discovery Labs KL4 Surfactant Granted Orphan Drug Designation for the Treatment of CF

by BEF

CF News, Therapies

March 19, 2019

Discovery Laboratories, Inc. today announced that the Office of Orphan Products Development of the United States Food and Drug Administration (FDA) has granted orphan drug designation to Discovery’s KL4 surfactant for the treatment of cystic fibrosis (CF). Orphan designation provides for up to seven years...

Pharmaxis Announces Positive Combined Phase 3 CF Trial Results

by BEF

CF News, Therapies

March 19, 2019

Pharmaceutical company Pharmaxis today announced significant results of pooled data from its two large scale six month Phase III trials of Bronchitol (inhaled mannitol) in people with cystic fibrosis. The combined results have been presented for the first time at the North American Cystic Fibrosis Conference...

Gilead’s Cayston Beats Tobramycin Inhalation Solution in Six-Month Head-to-Head Study

by BEF

CF News, Therapies

March 19, 2019

Gilead Sciences, Inc. announced that its head-to-head Phase III clinical trial of Cayston® (aztreonam for inhalation solution) versus tobramycin inhalation solution (TIS) in cystic fibrosis (CF) patients with Pseudomonas aeruginosa (P. aeruginosa) achieved its co-primary endpoint of superiority of Cayston for mean actual change in...

Analysis Shows TOBI Associated With Reduced Mortality in CF Patients With Common Lung Infection

by BEF

CF News, Therapies

March 19, 2019

A new analysis of data from more than 12,000 people with cystic fibrosis (CF) and Pseudomonas aeruginosa (Pa) lung infection in the Cystic Fibrosis Foundation's Patient Registry shows that use of TOBI® (Tobramycin Inhalation Solution, USP) was associated with a 21% reduction in mortality in...

Vertex Pharmaceuticals Clinical Trial to Evaluate Combo of VX-770 and VX-809 Targeting CFTR Protein

by BEF

CF News, Therapies

March 19, 2019

Vertex Pharmaceuticals Inc. today announced the initiation of a Phase 2a clinical trial that will evaluate multiple combinations of VX-770 and VX-809, investigational oral cystic fibrosis transmembrane conductance regulator (CFTR) modulators for the treatment of cystic fibrosis (CF). The trial is designed to evaluate the...

PTC Therapeutics Awarded $1.6 Million FDA Grant to Support Ongoing Phase 3 Study of Ataluren

by BEF

CF News, Therapies

March 19, 2019

PTC Therapeutics, Inc. (PTC) today announced a grant award of approximately $1.6 million from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OPD) to support an ongoing Phase 3 study of ataluren in patients with nonsense mutation cystic fibrosis (nmCF). The...

Author: BEF

Phase 3 Trial of Ataluren Expected to be Completed in 2011

Denufosol Phase 3 Trial Published in Leading Medical Journal

New England Journal of Medicine Publishes Phase 2 Study of VX-770 for Treating Cause of CF

Phase 2 Results Show Ataluren Restores Production of Functional CFTR Protein

Discovery Labs KL4 Surfactant Granted Orphan Drug Designation for the Treatment of CF

Pharmaxis Announces Positive Combined Phase 3 CF Trial Results

Gilead’s Cayston Beats Tobramycin Inhalation Solution in Six-Month Head-to-Head Study

Analysis Shows TOBI Associated With Reduced Mortality in CF Patients With Common Lung Infection

Vertex Pharmaceuticals Clinical Trial to Evaluate Combo of VX-770 and VX-809 Targeting CFTR Protein

PTC Therapeutics Awarded $1.6 Million FDA Grant to Support Ongoing Phase 3 Study of Ataluren

Never miss an update. Subscribe to our emails!